Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...

By combining Panbela's polyamine metabolic inhibitor platform ... I believe the combination of immunotherapy and metabolic pathway platforms could create powerful synergies in enhancing patient ...

Researchers reveal that spermidine-mediated acetylhypusination of RIPK1 suppresses necroptosis and insulin resistance, ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

Our lead assets ivospemin, eflornithine, and Flynpovi target the polyamine pathway in ways that could complement ImmunityBio's natural killer cell and killer T cell activation technology. The ...

Panbela Therapeutics, Inc. ( (PBLA) ) has released its Q3 earnings. Here is a breakdown of the information Panbela Therapeutics, Inc. presented ...

Up to $12.0 million financing commitment secured from strategic investor, Nant Capital. First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 ...

It might be possible for people in the future to consume BHB-Phe to drive weight loss without restricting carbohydrates in ...

Blood stem cells develop through different stages to become fully mature red blood cells. This fundamental biologic process ...